Clinical Trials Logo
  1. Home
  2. Locally Advanced Cancer
  3. NCT05942742

Estimation of Tumor Response With Linac MRI-guided Adaptive Radiotherapy for Locally Advanced Cervical Cancer — Gynecolunity  

Locally Advanced Cancer Clinical Trial

Official title:
Estimation of Tumor Response With Linac MRI-guided Adaptive Radiotherapy for Locally Advanced Cervical Cancer

Clinical Trial Summary

The management of locally advanced cervical cancer (Figo >IB) is based on radiochemotherapy (RCT) followed by brachytherapy. At present there is no personalized treatment, all patients undergoing radiochemotherapy will follow a conventional treatment by external radiotherapy (46 Gy in 23 sessions associated with cisplatin (CDDP) weekly) and brachytherapy to achieve a total equivalent biological dose around 80-90 Gy).The efficacy of this treatment has been proven for most patients, almost 80% being in complete response after RCT. Nevertheless, on an individual scale, there remains a significant variation in the tumor response, with patients who respond from the first week of treatment, "early responders" or, on the contrary, others who present significant tumor residues after external beam radiotherapy.Various macroscopic tumor volume (GTV) response patterns have been identified based on magnetic resonance imaging (MRI) at diagnosis and MRI before brachytherapy, implying very different clinical target volumes for brachytherapy technique. The difference in tumor volume response has been identified as having a major impact on treatment response. This is the first study attempting to evaluate tumor response in real time during radiochemotherapy treatment. Knowing the tumor response during treatment will make it possible to modify the management of locally advanced cervical cancer, several therapeutic options might then be discussed depending on the early response to treatment: dose de-escalation for early responders, reduction of time total treatment, personalization of brachytherapy management (technique and dose). This observational study will allow rapid identification of responder and non-responder patients and might be used as a basis for personalized treatment strategies

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05942742
Study type Observational
Source Hospices Civils de Lyon
Contact
Status Recruiting
Phase
Start date June 1, 2022
Completion date November 1, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT04143230 - Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool N/A
Terminated NCT03119428 - A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT03806309 - Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Phase 2
Active, not recruiting NCT04016142 - Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT03013010 - PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy Phase 3
Active, not recruiting NCT03794635 - An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer N/A
Recruiting NCT04945928 - Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC N/A